- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: December 2017
- Public Summary Document (PSD) December 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) December 2017 PBAC Meeting - Word
Adalimumab – December 2017
Adalimumab: Injection 40 mg in 0.4 mL pre-filled syringe and Injection 40 mg in 0.4 mL pre-filled pen; Humira®
Last updated
13 April 2018